Stocks and Investing Stocks and Investing
Mon, November 28, 2022
Fri, November 25, 2022
Thu, November 24, 2022
Wed, November 23, 2022

David Amsellem Maintained (TEVA) at Sell with Decreased Target to $7 on, Nov 23rd, 2022


Published on 2024-10-28 00:20:14 - WOPRAI, David Amsellem
  Print publication without navigation


David Amsellem of Piper Sandler, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Sell with Decreased Target from $8 to $7 on, Nov 23rd, 2022.

David has made no other calls on TEVA in the last 4 months.



There are 5 other peers that have a rating on TEVA. Out of the 5 peers that are also analyzing TEVA, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Gary Nachman of "BMO Capital" Maintained at Hold with Decreased Target to $10 on, Monday, November 7th, 2022
  • Nathan Rich of "Goldman Sachs" Maintained at Hold with Increased Target to $10 on, Tuesday, August 2nd, 2022


These are the ratings of the 3 analyists that currently disagree with David


  • Chris Schott of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $10 on, Monday, November 14th, 2022
  • Glen Santangelo of "Jefferies" Initiated at Strong Buy and Held Target at $10 on, Friday, October 21st, 2022
  • Jason Gerberry of "B of A Securities" Upgraded from Hold to Strong Buy and Increased Target to $13 on, Friday, August 5th, 2022
Contributing Sources